封面
市场调查报告书
商品编码
1706786

PD-1抑制剂药物市场-全球产业分析、规模、份额、成长、趋势及预测(2025-2035)

PD-1 Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日期: | 出版商: Transparency Market Research | 英文 242 Pages | 商品交期: 2-10个工作天内

价格

PD-1抑制剂药物市场-报告范围

TMR 关于全球 PD-1 抑制剂药物市场的报告研究了过去和当前的成长趋势和机会,以获得 2025 年至 2035 年预测期内市场指标的宝贵见解。该报告提供了 2019 年至 2035 年期间全球 PD-1 抑制剂药物市场的收入,以 2025 年为基准年,2035 年为预测年。报告中也提供了2025年至2035年全球PD-1抑制剂药物市场的年复合成长率(CAGR%)。

该报告是经过广泛研究后编写的。初步研究涉及大部分研究工作,其中分析师对关键意见领袖、行业领导者和舆论製造者进行了访谈。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件,以了解 PD-1 抑制剂药物市场。

市场概况
2024 年的市场价值 414亿美元
2035年的市场价值 2015亿美元
复合年增长率 15.5%

该报告深入探讨了全球 PD-1 抑制剂药物市场的竞争格局。已经确定了全球 PD-1 抑制剂药物市场的主要参与者,并根据各种属性对每个参与者进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告介绍的全球 PD-1 抑制剂药物市场参与者的属性。

目录

第一章:前言

第二章:假设与研究方法

第三章:执行摘要:全球市场

第四章:市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2035年全球市场分析与预测

第五章:关键见解

  • 主要地区/国家的监管格局
  • 市场趋势
  • 波特五力分析
  • PESTEL分析
  • 最终用户的关键购买指标
  • 品牌和定价分析
  • 重要产业活动
  • 国家/地区流行病学

第六章:全球市场分析与预测:依药物类型

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2035 年药品市场价值预测
    • 帕博利珠单抗
    • 纳武单抗
    • 西米普利单抗
    • 达他利单抗
    • 其他的
  • 不同药物类型的市场吸引力

第七章:全球市场分析与预测:按适应症

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2035 年各适应症市场价值预测
    • 黑色素瘤
    • 霍奇金淋巴瘤
    • 非小细胞肺癌
    • 肾癌
    • 头颈癌
    • 胃癌
    • 其他的
  • 市场吸引力(按适应症)

第八章:全球市场分析与预测:按配销通路

  • 介绍与定义
  • 主要发现/进展
  • 2020-2035年配销通路市场价值预测
    • 医院药房
    • 零售药局
    • 网路药局
  • 配销通路的市场吸引力

第九章:全球市场分析与预测:按地区

  • 主要发现
  • 各地区市场价值预测
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 各国家/地区市场吸引力

第十章:北美市场分析与预测

  • 我们
  • 加拿大

第 11 章:欧洲市场分析与预测

  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区

第十二章:亚太市场分析与预测

  • 中国
  • 日本
  • 印度
  • 澳洲和纽西兰
  • 亚太其他地区

第十三章:拉丁美洲市场分析与预测

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第 14 章:中东和非洲市场分析与预测

  • 海湾合作委员会国家
  • 南非
  • 中东和非洲其他地区

第 15 章:竞争格局

  • 市场参与者 - 竞争矩阵(依公司层级和规模)
  • 各公司市占率分析(2024 年)
  • 公司简介
    • Akeso Biopharma Co., Ltd.
    • Alphamab Oncology
    • Amgen Inc.
    • AstraZeneca
    • BeiGene LTD.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company.
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • GSK plc.
    • Innovent
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • Merck & Co., Inc.
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH.
    • Other prominent players
Product Code: TMRGL86486

PD-1 Inhibitor Drugs Market - Scope of Report

TMR's report on the global PD-1 inhibitor drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global PD-1 inhibitor drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PD-1 inhibitor drugs market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PD-1 inhibitor drugs market.

Market Snapshot
Market Value in 2024US$ 41.4 Bn
Market Value in 2035US$ 201.5 Bn
CAGR15.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PD-1 inhibitor drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PD-1 inhibitor drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PD-1 inhibitor drugs market.

The report delves into the competitive landscape of the global PD-1 inhibitor drugs market. Key players operating in the global PD-1 inhibitor drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PD-1 inhibitor drugs market profiled in this report.

Key Questions Answered in Global PD-1 inhibitor drugs Market Report:

  • What is the sales/revenue generated by PD-1 inhibitor drugs across all regions during the forecast period?
  • What are the opportunities in the global PD-1 inhibitor drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global PD-1 inhibitor drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PD-1 inhibitor drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PD-1 inhibitor drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global PD-1 Inhibitor Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Regulatory Landscape across Key Regions / Countries
  • 5.2. PD-1 Inhibitor Drugs Market Trends
  • 5.3. PORTER's Five Forces Analysis
  • 5.4. PESTEL Analysis
  • 5.5. Key Purchase Metrics for End-users
  • 5.6. Brand and Pricing Analysis
  • 5.7. Key Industry Events
  • 5.8. Epidemiology by Country/Region

6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2020-2035
    • 6.3.1. Pembrolizumab
    • 6.3.2. Nivolumab
    • 6.3.3. Cemiplimab
    • 6.3.4. Dostarlimab
    • 6.3.5. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Indication, 2020-2035
    • 7.3.1. Melanoma
    • 7.3.2. Hodgkin Lymphoma
    • 7.3.3. Non-Small Cell Lung Cancer
    • 7.3.4. Kidney Cancer
    • 7.3.5. Head and Neck Cancers
    • 7.3.6. Stomach Cancer
    • 7.3.7. Others
  • 7.4. Market Attractiveness By Indication

8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness By Distribution Channel

9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2020-2035
    • 10.2.1. Pembrolizumab
    • 10.2.2. Nivolumab
    • 10.2.3. Cemiplimab
    • 10.2.4. Dostarlimab
    • 10.2.5. Others
  • 10.3. Market Value Forecast By Indication, 2020-2035
    • 10.3.1. Melanoma
    • 10.3.2. Hodgkin Lymphoma
    • 10.3.3. Non-Small Cell Lung Cancer
    • 10.3.4. Kidney Cancer
    • 10.3.5. Head and Neck Cancers
    • 10.3.6. Stomach Cancer
    • 10.3.7. Others
  • 10.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Pembrolizumab
    • 11.2.2. Nivolumab
    • 11.2.3. Cemiplimab
    • 11.2.4. Dostarlimab
    • 11.2.5. Others
  • 11.3. Market Value Forecast By Indication, 2020-2035
    • 11.3.1. Melanoma
    • 11.3.2. Hodgkin Lymphoma
    • 11.3.3. Non-Small Cell Lung Cancer
    • 11.3.4. Kidney Cancer
    • 11.3.5. Head and Neck Cancers
    • 11.3.6. Stomach Cancer
    • 11.3.7. Others
  • 11.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Pembrolizumab
    • 12.2.2. Nivolumab
    • 12.2.3. Cemiplimab
    • 12.2.4. Dostarlimab
    • 12.2.5. Others
  • 12.3. Market Value Forecast By Indication, 2020-2035
    • 12.3.1. Melanoma
    • 12.3.2. Hodgkin Lymphoma
    • 12.3.3. Non-Small Cell Lung Cancer
    • 12.3.4. Kidney Cancer
    • 12.3.5. Head and Neck Cancers
    • 12.3.6. Stomach Cancer
    • 12.3.7. Others
  • 12.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Pembrolizumab
    • 13.2.2. Nivolumab
    • 13.2.3. Cemiplimab
    • 13.2.4. Dostarlimab
    • 13.2.5. Others
  • 13.3. Market Value Forecast By Indication, 2020-2035
    • 13.3.1. Melanoma
    • 13.3.2. Hodgkin Lymphoma
    • 13.3.3. Non-Small Cell Lung Cancer
    • 13.3.4. Kidney Cancer
    • 13.3.5. Head and Neck Cancers
    • 13.3.6. Stomach Cancer
    • 13.3.7. Others
  • 13.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Pembrolizumab
    • 14.2.2. Nivolumab
    • 14.2.3. Cemiplimab
    • 14.2.4. Dostarlimab
    • 14.2.5. Others
  • 14.3. Market Value Forecast By Indication, 2020-2035
    • 14.3.1. Melanoma
    • 14.3.2. Hodgkin Lymphoma
    • 14.3.3. Non-Small Cell Lung Cancer
    • 14.3.4. Kidney Cancer
    • 14.3.5. Head and Neck Cancers
    • 14.3.6. Stomach Cancer
    • 14.3.7. Others
  • 14.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Akeso Biopharma Co., Ltd.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Development
    • 15.3.2. Alphamab Oncology
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Development
    • 15.3.3. Amgen Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Development
    • 15.3.4. AstraZeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Development
    • 15.3.5. BeiGene LTD.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Development
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Development
    • 15.3.7. Eli Lilly and Company.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Development
    • 15.3.8. F. Hoffmann-La Roche Ltd
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Development
    • 15.3.9. Gilead Sciences, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Development
    • 15.3.10. GSK plc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Development
    • 15.3.11. Innovent
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Development
    • 15.3.12. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Development
    • 15.3.13. Merck & Co., Inc.
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Product Portfolio
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Development
    • 15.3.14. Eli Lilly and Company
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Financial Overview
      • 15.3.14.3. Product Portfolio
      • 15.3.14.4. Business Strategies
      • 15.3.14.5. Recent Development
    • 15.3.15. Boehringer Ingelheim International GmbH.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Financial Overview
      • 15.3.15.3. Product Portfolio
      • 15.3.15.4. Business Strategies
      • 15.3.15.5. Recent Development
    • 15.3.16. Other prominent players
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Financial Overview
      • 15.3.16.3. Product Portfolio
      • 15.3.16.4. Business Strategies
      • 15.3.16.5. Recent Development

List of Tables

  • Table 01: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 02: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 03: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 04: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, By Region, 2020-2035
  • Table 05: North America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 07: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 08: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 09: Europe - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 10: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 11: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 12: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 13: Asia Pacific - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 14: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 15: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 16: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 17: Latin America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 18: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 19: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 20: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 21: Middle East & Africa - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 22: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 23: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 24: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 02: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 03: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Pembrolizumab, 2020-2035
  • Figure 04: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Nivolumab, 2020-2035
  • Figure 05: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Cemiplimab, 2020-2035
  • Figure 06: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Dostarlimab, 2020-2037
  • Figure 07: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Others, 2020-2038
  • Figure 08: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 09: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 10: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Melanoma, 2020-2035
  • Figure 11: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Hodgkin Lymphoma, 2020-2035
  • Figure 12: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Non-Small Cell Lung Cancer, 2020-2035
  • Figure 13: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Kidney Cancer, 2020-2035
  • Figure 14: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Stomach Cancer, 2020-2035
  • Figure 15: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 16: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 17: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 18: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
  • Figure 19: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
  • Figure 20: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
  • Figure 21: Global PD-1 Inhibitor Drugs Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 22: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, By Region, 2024-2034
  • Figure 23: North America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 24: North America - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 25: North America - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 26: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 27: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 28: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 29: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 30: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 31: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 32: Europe - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 33: Europe - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 34: Europe - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 35: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 36: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 37: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 38: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 39: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 40: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 41: Asia Pacific - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 42: Asia Pacific - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 43: Asia Pacific - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 44: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 45: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 46: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 47: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 48: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 49: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 50: Latin America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 51: Latin America - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 52: Latin America - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 53: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 54: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 55: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 56: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 57: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 58: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 59: Middle East & Africa - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 60: Middle East & Africa - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 61: Middle East & Africa - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 62: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 63: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 64: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 65: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 66: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 67: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035